Cargando…

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A

BACKGROUND: N8‐GP is an extended half‐life recombinant factor VIII developed for prophylaxis and treatment of bleeds in patients with hemophilia A. OBJECTIVE: To assess pharmacokinetic (PK) characteristics of N8‐GP in previously treated patients with severe hemophilia A, model the time spent at hemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chowdary, Pratima, Carcao, Manuel, Holme, Pål A., Jiménez‐Yuste, Victor, Lentz, Steven R., Møss, Judi, Poulsen, Lone H., Shen, Chunduo, Tosetto, Alberto, Wheeler, Allison, Santagostino, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Online‐only Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611478/ https://www.ncbi.nlm.nih.gov/pubmed/31294338 http://dx.doi.org/10.1002/rth2.12220

Ejemplares similares

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model
por: Tiede, Andreas, et al.
Publicado: (2020)

Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials
por: Tosetto, Alberto, et al.
Publicado: (2020)

Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)
por: Curry, Nicola, et al.
Publicado: (2019)

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A
por: Di Minno, Giovanni, et al.
Publicado: (2019)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2016)

Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response
por: Chowdary, Pratima, et al.
Publicado: (2021)

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
por: Yu, Jacky K., et al.
Publicado: (2019)

Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
por: Klamroth, Robert, et al.
Publicado: (2021)

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
por: Colombo, Giorgio L, et al.
Publicado: (2011)

PB2653: SYNTHESIS OF MAGNETIC NANOPARTICLES SUITABLE FOR PURIFICATION FACTOR VIII
por: Shurko, Nataliya, et al.
Publicado: (2023)

PB2323: ACQUIRED HEMOPHILIA: A CASE REPORT
por: Haddad, N., et al.
Publicado: (2022)

Hematuria in aging men with hemophilia: Association with factor prophylaxis
por: Qvigstad, Christian, et al.
Publicado: (2020)

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
por: Lentz, Steven R., et al.
Publicado: (2022)

Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review
por: Sun, Jing, et al.
Publicado: (2021)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
por: Chowdary, Pratima, et al.
Publicado: (2022)

PB2329: ACQUIRED HEMOPHILIA-POTENTIALLY FATAL IF NOT TREATED PROMPTLY
por: Stankovikj, S., et al.
Publicado: (2022)

Long‐term safety and efficacy of N8‐GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5
por: Šaulytė Trakymienė, Sonata, et al.
Publicado: (2020)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis
por: McEneny-King, Alanna, et al.
Publicado: (2017)

Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
por: Jiménez‐Yuste, Víctor, et al.
Publicado: (2022)

Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients
por: Preijers, Tim, et al.
Publicado: (2021)

Principles of care for acquired hemophilia
por: Dolan, Gerry, et al.
Publicado: (2021)

PB2655: EVALUATION OF THE EFFICACY AND SAFETY IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH ACQUIRED FACTOR VIII AND IX INHIBITOR
por: Koyun, Derya, et al.
Publicado: (2023)

PB2647: USE OF EMICIZUMAB FOR THE TREATMENT OF ACQUIRED HEMOPHILIA A: A SYSTEMATIC REVIEW
por: Al-Housni, Zainab, et al.
Publicado: (2023)

PB2649: THE SURGICAL OUTCOMES IN PEDIATRICS PATIENTS WITH HEMOPHILIA, THE ROYAL HOSPITAL EXPERIENCE, OMAN
por: Al Hajri, Alia, et al.
Publicado: (2023)

Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
por: Jonsson, Fredrik, et al.
Publicado: (2021)

PB2654: RARE BLEEDING DISORDERS: LONG-TERM EXPERIENCE FROM A HEMOPHILIA CENTER
por: Meimaridis, Antonios, et al.
Publicado: (2023)

PB2643: EFFICACY OF REDUCED-DOSE EMICIZUMAB IN HEMOPHILIA A WITH INHIBITORS: REAL WORLD EXPERIENCE IN MALAYSIA
por: Tang, Andy Sing Ong, et al.
Publicado: (2023)

Focusing in on use of pharmacokinetic profiles in routine hemophilia care
por: Croteau, Stacy E., et al.
Publicado: (2018)

Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis
por: Croteau, Stacy E, et al.
Publicado: (2021)

PB2648: THE RELATIONSHIP BETWEEN BALANCE CONFIDENCE, KINESIOPHOBIA AND LEG MUSCLE STRENGTH AMONG ADULT HEMOPHILIA PATIENTS
por: Aykar, Sercan Onal, et al.
Publicado: (2023)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

PB2674: CLINICAL, NEUROIMAGING, AND BEHAVIORAL RISK FACTORS FOR NEUROCOGNITIVE IMPAIRMENT IN CHINESE PATIENTS WITH HEMOPHILIA: A MULTICENTER STUDY
por: Cheung, Yin Ting, et al.
Publicado: (2023)

A new recombinant factor VIII: from genetics to clinical use
por: Santagostino, Elena
Publicado: (2014)

Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study
por: Stimec, Jennifer, et al.
Publicado: (2021)

Modified Factor VIII and Factor IX recombinant products
por: Santagostino, Elena, et al.
Publicado: (2018)

Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f9ji3g3239ne3vgj0tnk8t2da9